MedTrace Logo

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

NCT04949191 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.

Conditions

  • Advanced Malignancies

Interventions

DRUG

Pemigatinib

Pemigatinib tablets taken by mouth once daily as per protocol

DRUG

Retifanlimab

Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)

DRUG

Pembrolizumab

Commercially labeled products

Sponsors & Collaborators

Principal Investigators

  • Peter Langmuir · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-08
Primary Completion
2024-04-11
Completion
2024-04-11
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • Italy
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04949191 on ClinicalTrials.gov